- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00201305
Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
Prospective Phase II Randomized Trial-Weekly Gemcitabine Plus High-Dose 5-Fluorouracil/ Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
5-FU has been the mainstay of chemotherapeutic agents for gastrointestinal malignancies. The use of weekly 24-hour infusion of HDFL produces high clinical response in a variety of cancers, including colorectal, gastric and breast cancers, with minimal chemotherapy-related toxicity. Gemcitabine is a synthesized deoxycytidine analogue that is metabolized to dFdCTP in tumor cells and results in inhibition of DNA synthesis and depletion of normal cellular nucleotide pool. It has been shown to be active in the treatment of pancreatic cancer and non-small cell lung cancer. Since the biliary tract and the pancreas share a common embryonic origin and cancers from both sites are characterized by resistance to most chemotherapeutic agents, we postulate that gemcitabine may also be effective for cancer of the biliary tract. In our institution we have devised a regimen of weekly gemcitabine and 24-hour infusion of HDFL for patients with advanced or metastatic pancreatic adenocarcinoma. In 18 evaluable patients, 2 achieved a partial response and 3 minor response. The median duration of response was 4 months and the treatment-related toxicity was acceptable.
The eligibility criteria are patients with advanced or metastatic carcinoma of the biliary tract who are not candidates for curative surgical treatment; good performance status; no prior chemotherapy; clinical measurable tumor; good organ function and good compliance. Each cycle of chemotherapy consists of 4 weeks. On days 1, 8 and 15, gemcitabine will be given by 30-minute intravenous infusion and 5-FU and leucovorin by 24-hour continuous intravenous infusion. The dose of gemcitabine will be 1000 mg/m2. The doses of 5-FU will be 2000 mg/m2 and leucovorin, 300 mg/m2. Treatment will continue until disease progresses or prohibitive toxicity develops. For patients with complete response (CR), chemotherapy will continue for 3 additional courses after the documentation of CR. Estimated time for patient accrual is 3 years.
Studietyp
Inskrivning
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Histologically proven carcinoma of the biliary tract, including gallbladder carcinoma and cholangiocarcinoma. The disease should be either locally advanced to the extent that curative surgery is impossible or with documented distant metastasis.
- Bi-dimensionally measurable disease by physical examination or image study (roentgenogram or computed tomography (CT) scan).
- Age > 18 years. For patients older than 70 years of age, detailed evaluation of the organ function reserves must be done before enrollment unto protocol treatment.
- Karnofsky performance status> 60%
- Adequate bone marrow reserves, defined as white blood cell (WBC)>4,000/ml, absolute neutrophil count (ANC)> 1,500/ml, platelet> 150,000/ml.
- Liver transaminases <5 times upper normal limits; total bilirubin <3 mg/dl; serum creatinine < 1.5 mg/dl
- Serum triglyceride level >70 mg/dl
- No prior cytotoxic chemotherapy. Previous radiotherapy is allowed if the treatment was completed at least 6 weeks before the enrollment onto this study.
- Patients of childbearing age should have effective contraception during the study period.
- All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional guidelines.
Exclusion criteria:
- Patients who are receiving concurrent radiotherapy, chemotherapy or other experimental therapy.
- Patients who refuse port-A catheter implantation
- Patients with brain or leptomeningeal metastases.
- Patients who have significant cardiac arrhythmia or acute myocardial infarction within 6 months before entry.
- Patients who have major systemic diseases that the attending physicians considered inappropriate for systemic chemotherapy.
- Life expectancy less than 2 months.
- Pregnant or nursing women may not participate. Women or men with reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- Patients who have previous malignancy except for the following: adequately treated basal cell or squamous cell skin cancers, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any cancer from which the patient has been disease-free for 5 years.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
To determine the response rate of weekly gemcitabine plus high-dose 5-FU/leucovorin chemotherapy for patients with advanced or metastatic biliary tract cancer.
|
Sekundära resultatmått
Resultatmått |
---|
To determine:
|
1.Toxicity profile of gemcitabine plus high-dose 5-FU/leucovorin chemotherapy for advanced or metastatic biliary tract cancer.
|
2.Time to disease progression
|
3.Overall survival
|
4.Quality of life
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Ann-Li Cheng, PHD, National Taiwan University Hospital
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Gallvägssjukdomar
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Skyddsmedel
- Mikronäringsämnen
- Vitaminer
- Motgift
- Vitamin B-komplex
- Gemcitabin
- Leucovorin
Andra studie-ID-nummer
- T3202
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Gallvägssjukdom
-
Federal University of Rio Grande do SulRekryteringTandimplantat misslyckades | Sinus TractBrasilien
-
Majmaah UniversityHar inte rekryterat ännuSinus Tract | Singelbesök | Flera besök | Enkel kon obturationsteknik | Biokeramisk tätning
-
Maastricht University Medical CenterWingate Institute of NeurogastroenterologyRekryteringfMRI | Transkutan vagus nervstimulering (tVNS) | Nucleus of the Solitary Tract (NTS)Nederländerna, Storbritannien
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; Swedish International Development Cooperation Agency...Avslutad
-
Assiut UniversityHar inte rekryterat ännuCalculus Biliary
-
Sarah Magdy AbdelmohsenAvslutad
-
Anhui Provincial HospitalAvslutad
-
National Cheng-Kung University HospitalAvslutadNeoplasmer | Sten - Biliary | GallvägarTaiwan
-
Children's Hospital of Fudan UniversityShanghai Zhongshan Hospital; Shanghai Children's Medical CenterRekryteringMedfödd hjärtsjukdom | Höger kammare Utflöde Tract Frånvarande | LungventilstörningarKina
-
Chulalongkorn UniversityBoston Scientific CorporationAvslutadKolangit, sklerosering | Vanliga gallvägssjukdomar | Sten - Biliary
Kliniska prövningar på Gemcitabine+5FU+Leucovorin
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... och andra samarbetspartnersOkändBukspottskörtelcancerTaiwan
-
Zealand University HospitalRekryteringIntestinala neoplasmer | Kolorektal cancer | Rektal cancer | Rektal neoplasmer | Kolorektal neoplasma | Kemoterapi effekt | TarmsjukdomDanmark
-
Marks, John, M.D.AvslutadRektal neoplasmerFörenta staterna
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanAvslutadKolorektala neoplasmerJapan
-
Novartis PharmaceuticalsAktiv, inte rekryterandeMetastaserande kolorektal cancerKanada, Taiwan, Belgien, Tyskland, Spanien, Italien, Tjeckien, Schweiz, Australien, Förenta staterna, Japan, Singapore, Storbritannien, Frankrike, Israel, Hong Kong, Korea, Republiken av
-
Institut du Cancer de Montpellier - Val d'AurelleAvslutadMetastaserande bukspottkörteladenokarcinomFrankrike
-
BioLineRx, Ltd.Merck Sharp & Dohme LLCAvslutadMetastaserande bukspottkörteladenokarcinomFörenta staterna, Israel, Korea, Republiken av, Spanien
-
Hospital Alemão Oswaldo CruzRekryteringRektal cancer | KonsolideringBrasilien, Argentina, Uruguay
-
AHS Cancer Control AlbertaOkänd
-
Devalingam MahalingamAmgenIndragenBukspottskörtelcancer | Metastaserad pankreascancer | Ooperbar pankreascancer | KRAS P.G12CFörenta staterna